Nasdaq-listed Athira Pharma has appointed Mark Worthington as the company’s general counsel, effective June 1.
Worthington joins Athira having been a partner with Summit Law Group for 24 years. According to his law firm biography, Worthington has focused his practice on corporate and securities law, advising start-ups, emerging growth companies and public companies.
During his time with Summit Law Group he has worked on M&A and other corporate transactions including angel, venture capital and private equity financings as well as initial, secondary and follow-on public offerings. He has also advised private and public companies on corporate governance and compliance issues.
Athira, which closed its IPO last September, is a late clinical-stage biopharmaceutical company focused on developing molecules to restore neuronal health and stop neurodegeneration. Worthington is Athira’s first general counsel as a public company. Christina Thomson, who was previously general counsel, left the company in July 2020 to join Sierra Oncology.
‘We have worked with Mark for many years and are excited he is now joining Athira,’ president and CEO Leen Kawas says in a statement. ‘He brings a wealth of experience providing legal and strategic business counsel to private and public companies including life science companies. As our general counsel, Mark will be integrally involved in Athira’s business growth and strategic plans.’
Ben Maiden
Ben Maiden is the editor-at-large of Governance Intelligence, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...
